The role of the sympathetic nervous system in linking obesity with hypertension in white versus black Americans

Current Hypertension Reports

Volumn 5, Issue 3, 2003, Pages 269-272

  Eslami, Pirooz ^a   Tuck, Michael ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INSULIN; LEPTIN; LISINOPRIL; NORADRENALIN;

ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC STIMULATION; AFRICAN AMERICAN; ANTIHYPERTENSIVE ACTIVITY; BROWN ADIPOSE TISSUE; CAUCASIAN; DISEASE ASSOCIATION; ENERGY EXPENDITURE; ETHNIC DIFFERENCE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; MUSCLE METABOLISM; NORADRENALIN BLOOD LEVEL; OBESITY; RACE DIFFERENCE; REVIEW; SYMPATHETIC FUNCTION; WEIGHT GAIN; ADRENERGIC SYSTEM; COMORBIDITY; COMPARATIVE STUDY; ENERGY METABOLISM; ETHNOLOGY; NEGRO; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

AFRICAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; ENERGY METABOLISM; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; LEPTIN; MUSCLE, SKELETAL; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 0141799751     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0031-z     Document Type: Review

References (39)

1. Dustan HP: Obesity and hypertension in blacks. Cardiovasc Drugs Ther 1990, 4(Suppl 2):395-402.
2. Fray JCS, Douglas JG: Pathophysiology of Hypertension in Blacks. New York, NY Oxford University Press; 1993.
3. Cooper R, Rotimi C: Hypertension in blacks. Am J Hypertens 1997, 7:804-812.
4. Calhoun DA: Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. Am J Med Sci 1992, 5:304-306.
5. CalHoun DA, Oparil S: Racial diferences in the pathogenesis of hypertension. Am J Med Sci 1995, 310:S86-S90.
6. Liu K, Ruth KJ, Flack JM, et al.: Blood pressure in young blacks and whites: relevance of obesity and lifestyle factors in determining differences: (The Cardia Study). Circulation 1993, 1:60.
7. Neser WB, Thomas J, Semenya K, et al.: Obesity and hypertension in a longitudinal study of black physicians: (The Meharry Cohort Study). J Chron Dis 1986,39:105-113.
8. Tuck ML, Sowers JR, Dornfeld L, et al.: Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) 1983, 102:252-257.
9. Young JB, MacDonald IA: Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 1992, 16:959-967.
10. Gonzalez-Trapaga JL, Nelesen RA, Dimsdale JE, et al.: Plasma Epinephrine levels in hypertension and across gender and ethinicity. Life Sci 2000, 66:2383-2392.
11. Mikhail N, Golub MS, Tuck ML: Obesity and hypertension. Prog Cardio Dis 1999,42:39-58.
12. Grossman E, Chang PC, Hoffman A, et al.: Tracer norepinephrine kinetics: dependence on regional blood flow and the site of infusion. Am J Physiol 1991, 260:R946-R952.
13. Eisenhofer G, Esler MD, Goldstein DS, et al.: Neuronal uptake, metabolism, and release of tritium-labeled norepinephrine during assessment of its plasma kinetics. Am J Physiol 1991, 261:E505-E515.
14. Esler MD, Lambert G, Jennings GL: Increased regional sympathetic nerve activity in human hypertension: causes and consequences. J Hypertens 1990, 8(Suppl 7):S53-S57.
15. Vaz M, Jennings GL, Turner A, et al.: Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997, 6:3423-3429.
16. Esler M, Lambert G, Vaz M, et al.: Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Clin Exp Hypertens 1997, 19:577-590.
17. Masuo K: Obesity-related hypertension: role of sympathetic nervous system, insulin, and leptin. Curr Hypertens Rep 2002, 2:112-118.
18. Anderson EA, Sinkey CA, Lawton WJ, Mark AL: Elevated sympathetic nerve activity in borderline hypertensive man: Evidence from direct intraneuronal recordings. Hypertension 1989, 14:177-183.
19. Jones PP, Snitker S, Skinner JS, Ravussin E: Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. Am J Physiol 1996, 270:363-366.
20. Gudbjornsdottir S, Lonnroth P, Sverrisdottir YB, et al.: Sympathetic nerve activity and insulin in obese normotensive and hypertensive men. Hypertension 1996, 27:276-280.
21. Weyer C, Pratley RE, Snitker S, et al.: Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000, 36:531-537.
22. Spraul M, Ravussin E, Fontvieille AM, et al.: Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. J Clin Invest 1993, 92:1730-1735.
23. Calhoun DA, Mutinga ML, Wyss JM, Oparil S: Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects. J Hypertens 1994, 12:1291-1296.
24. Abate NI, Mansour YH, Tuncel M, et al.: Overweight and sympathetic overactivity in black Americans. Hypertension 2001, 38:379-383.
25. Narkiewicz K, Van de Borne PJ, Cooley RL,et al.: Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998, 98:772-776.
26. Grassi G, Colombo M, Seravalle G, et al.: Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998, 31:64-67.
27. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14:S103-S115.
28. Haynes WG, Morgan DA, Sivitz WI, et al.: Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270-278.
29. O'Hare JA, Minaker KL, Meneilly CA, et al.: Effect of insulin on plasma norepinephrine and 3, 4 dihydroxyphenylalanine in obese men. Metabolism 1989, 38:322-329.
30. Anderson EA, Mark AL: The vasodilatory action of insulin. Implications for the insulin hypothesis in hypertension. Hypertension 1993, 21:136-141.
31. Corry DB, Truck ML: Insulin and glucoregulatory hormones: Implications for antihypertensive therapy. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley and Belfus; 1998:217-241.
32. Barron AD: Insulin and the vasculture - old actors, new roles. J Invest Med 1996, 8:406-412.
33. Scherrer U, Randin D, Vollenweinder P, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994, 94:2511-2515.
34. Masuo K, Mikami H, Ogihara T, Tuck ML: Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001, 14:530-538.
35. Reisen E, Weir MR, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patient. A Multicenter placebo-controlled trial. Hypertension 1997; 30(Pt1):145-155.
36. Corry DB, Tuck ML: Implications of glucoregulatory hormones in antihypertensive therapy. In Calcium Antagonists in Clinical Medicine, edn 3. Philadelphia: Hanley & Belfus; 2002:161-180.
37. Tuck ML: Obesity, the sympathetic nervous system and essential hypertension. Hypertension 1992, 19(Suppl 1):1-67-1-77.
38. Grassi G, Seravelle G, Cattaneo BM, et al.: Sympathetic activation in obese normotensive subjects. Hypertension 1995, 25:560-563.
39. Landsberg L: Insulin and the sympathetic nervous system in the pathophysiology of hypertension. Blood Press Suppl 1996, 1:25-29.